Category: antifungal resistance

  • Novo-backed $61m fundraising helps F2G prep for antifungal launch

    Anglo-Austrian biotech F2G has raised $60.8 million in venture financing to help it bring a drug for life-threatening fungal infections through late-stage development and onto the market. While these infections remain fairly rare, there is still a pressing need for new antifungals to provide treatment options when established therapies fail, and F2G is one of […]